PRNewswire - November 30, 2001
Since the delivery of drug supplies to Congo (Brazzaville) and Senegal as the first countries in the Boehringer Ingelheim VIRAMUNE® Donation Program in 2000, sixteen additional countries have been included. This increases the number of participating countries to a total of eighteen with 29 different projects.
"Providing effective interventions to prevent mother to child transmission of HIV in developing countries is a top priority for Axios and Boehringer Ingelheim," said Dr. Joseph Saba, Axios Chief Executive Officer. "We will spare no effort to facilitate access to VIRAMUNE for people with HIV in developing countries through Boehringer Ingelheim's generous donation. On this World AIDS Day, we celebrate the addition of Ukraine to the growing list of countries taking advantage of this important program, and the first of its kind in Eastern Europe."
The VIRAMUNE® Donation Program represents Boehringer Ingelheim's offer to provide VIRAMUNE® (nevirapine) free of charge for a period of five years to developing countries for use in the prevention of Mother to Child Transmission of HIV-1 (MTCT). Countries participating in the VIRAMUNE® Donation Program include: Burundi, Benin, Cameroon, Congo (Brazzaville), Ghana, Guyana, Ivory Coast, Kenya, Malawi, Namibia, Nigeria, Rwanda, Senegal, Sierra Leone, Uganda, Ukraine, Zambia and Zimbabwe.
Axios is an international company providing consultancy services, technical assistance and program implementation in healthcare in developing countries. Axios has extensive worldwide experience in private and public sector partnerships, in public health implementation programs and in creating appropriate alliances at political and technical levels. The Axios group consists of a multidisciplinary team with distinctive areas of expertise that works closely with local counterparts. Axios implementation projects currently include programs on Orphans and Vulnerable Children (OVC), Voluntary Counseling and Testing of HIV (VCT), Prevention of Mother-to-Child Transmission of HIV (MTCT), management of donations and programs to increase access to HIV-related drugs and care in developing countries.
For more information on Axios, please see the Internet website www.axios-group.com or www.viramune-donation-program.org, which provides readily available information about the status of the Program.
Contact: Ms Linda Sheaffer Axios International 33610 Solon Road - Suite B4 Solon, Ohio 44139 USA Phone: 1- 440-498-9151 Fax: 1- 440-248-1969 E mail: sheafferl@axiosint.com
Contact: Ms. Claire Brule' Axios International 7 Castlecourt Centre Castleknock Dublin 18 Ireland Phone: 353-1-820-8081 Fax: 353-1-820-8404 E mail: axios@axiosint.com
011130
PR011143
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. ÆGIS. All materials appearing on ÆGIS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content. Feedback/Contact Us.